CDC releases clinical guidance for providers during the Shingrix shortage

IAC Express

In light of the current shortage of recombinant zoster vaccine (Shingrix; GSK), CDC has added the following Q&A to its “Frequently Asked Questions About Shingrix” web page:

Q: What is the clinical guidance during the Shingrix delay?

A: Shingrix is the preferred shingles vaccine. You and patients should make every effort to ensure that two doses are administered within the recommended interval. If more than 6 months have elapsed since the first dose, administer the second dose when possible. Do not restart the vaccine series, and do not substitute Zostavax (zoster vaccine live) for the second dose of Shingrix. If you are out of Shingrix and a patient needs a second dose, the Vaccine Finder may be helpful for patients to locate other providers that have Shingrix.

CDC still recommends Zostavax for healthy adults 60 years and older to prevent shingles. This shingles vaccine may be used in certain cases, such as when a person prefers Zostavax or requests immediate vaccination and Shingrix is unavailable. Patients who have received Zostavax are recommended to subsequently receive Shingrix. Age and time since receipt of Zostavax may be considered to determine when to vaccinate with Shingrix (minimum interval of 8 weeks).